Otsuka

Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

• A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.
• Therapeutic Area Focus
  • Key product analysis and forecasting
• Neuroscience
  • Effexor (venlafaxine)
  • Pristiq (desvenlafaxine succinate)
• Gastroenterology
  • Protonix (pantoprazole)
  • Relistor (methylnaltrexone)
• Vaccines
  • Prevnar/Prevenar (7-valent glycoconjugate)
• Musculoskeletal
  • Enbrel (etanercept)
  • rhBMP-2/Inductos (dibotermin alpha)
• Women's Healthcare/Contraception
  • Lybrel/Anya (levonorgestral+ethinyloestradiol)
  • Oral contraceptives
  • Premarin (conjugated oestrogens)
• Anti-Infectives
  • Tazocin/Zosyn (tazobactam)
  • Tygacil (tigecycline)
• Haemophilia
  • BeneFIX (recombinant Factor IX)
  • ReFacto (recombinant Factor VIII)
• Immunology
  • Rapamune (sirolimus)
• Oncology
  • Torisel (temsirolimus)
• Operational Data
  • A wealth of background and detail
  • A full 5-year financial performance assessment
  • Key corporate events
  • Key agreements
  • Infrastructure
  • Subsidiaries and joint ventures